Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial.

MLA

Lotery, Andrew, et al. “Eplerenone for Chronic Central Serous Chorioretinopathy in Patients with Active, Previously Untreated Disease for More than 4 Months (VICI): A Randomised, Double-Blind, Placebo-Controlled Trial.” Lancet (London, England), vol. 395, no. 10220, Jan. 2020, pp. 294–303. EBSCOhost, https://doi.org/10.1016/S0140-6736(19)32981-2.

APA

Lotery, A., Sivaprasad, S., O’Connell, A., Harris, R. A., Culliford, L., Ellis, L., Cree, A., Madhusudhan, S., Behar-Cohen, F., Chakravarthy, U., Peto, T., Rogers, C. A., & Reeves, B. C. (2020). Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet (London, England), 395(10220), 294–303. https://doi.org/10.1016/S0140-6736(19)32981-2

Chicago

Lotery, Andrew, Sobha Sivaprasad, Abby O’Connell, Rosie A Harris, Lucy Culliford, Lucy Ellis, Angela Cree, et al. 2020. “Eplerenone for Chronic Central Serous Chorioretinopathy in Patients with Active, Previously Untreated Disease for More than 4 Months (VICI): A Randomised, Double-Blind, Placebo-Controlled Trial.” Lancet (London, England) 395 (10220): 294–303. doi:10.1016/S0140-6736(19)32981-2.